NO993627L - Anvendelse av en forbindelse for fremstilling av et legemiddel - Google Patents

Anvendelse av en forbindelse for fremstilling av et legemiddel

Info

Publication number
NO993627L
NO993627L NO993627A NO993627A NO993627L NO 993627 L NO993627 L NO 993627L NO 993627 A NO993627 A NO 993627A NO 993627 A NO993627 A NO 993627A NO 993627 L NO993627 L NO 993627L
Authority
NO
Norway
Prior art keywords
manufacture
medicament
compound
diseases
brain
Prior art date
Application number
NO993627A
Other languages
English (en)
Other versions
NO993627D0 (no
Inventor
Yasufumi Shirasaki
Hitoshi Yamaguchi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO993627L publication Critical patent/NO993627L/no
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO993627D0 publication Critical patent/NO993627D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Oppfinnelsen vedrører anvendelse av en kalmodulininhibitor for fremstilling av et legemiddel egnet til behandling og forebygging av forskjellige sykdommer i hjernen og ettersykdommer derav.
NO993627A 1993-05-25 1999-07-26 Anvendelse av en forbindelse for fremstilling av et legemiddel NO993627D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12293393 1993-05-25

Publications (2)

Publication Number Publication Date
NO993627L true NO993627L (no) 1994-11-28
NO993627D0 NO993627D0 (no) 1999-07-26

Family

ID=14848208

Family Applications (2)

Application Number Title Priority Date Filing Date
NO941915A NO941915L (no) 1993-05-25 1994-05-24 Madikament for nervebeskyttelse
NO993627A NO993627D0 (no) 1993-05-25 1999-07-26 Anvendelse av en forbindelse for fremstilling av et legemiddel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO941915A NO941915L (no) 1993-05-25 1994-05-24 Madikament for nervebeskyttelse

Country Status (10)

Country Link
US (2) US5661150A (no)
EP (1) EP0627219A1 (no)
CN (1) CN1100301A (no)
AU (2) AU684270B2 (no)
CA (1) CA2124284C (no)
FI (1) FI942400L (no)
NO (2) NO941915L (no)
PH (1) PH31213A (no)
RU (1) RU2135162C1 (no)
TW (1) TW309427B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2152941C1 (ru) * 1994-11-14 2000-07-20 Дайити Фармасьютикал Ко., Лтд. Кристаллический дигидрохлорид 3-[2-[4-(3-хлор-2-метилфенил)-1-пиперазинил]этил]-5,6-диметокси-1- (4-имидазолилметил)-1н-индазола и его 3,5-гидрат, способы их получения
CA2188816C (en) * 1996-04-23 2009-09-22 Takeda Chemical Industries, Ltd. Composition containing .alpha.-fodrin or .alpha.- fodrin fragment protein
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
DE19820224A1 (de) * 1998-05-06 1999-12-09 Markus Schott Bindungspartner und Verfahren zur kompetitiven Hemmung der Bindung zwischen NEF-Protein und Calmodulin, sowie Mittel und Verwendung bei HIV-Erkrankungen
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6105582A (en) * 1998-07-28 2000-08-22 Pranevicius; Osvaldas Cerebral blood outflow maintenance during intracranial hypertension
WO2002010768A2 (en) * 2000-07-31 2002-02-07 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
GB2377635B (en) * 2001-04-17 2005-10-19 Hoffmann La Roche Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
WO2007062862A2 (en) * 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
WO2024018245A1 (en) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en) 2023-01-20 2024-07-25 Institut National de la Santé et de la Recherche Médicale Autophagy activators for the treatment of rhabdomyolysis

Also Published As

Publication number Publication date
EP0627219A1 (en) 1994-12-07
NO941915L (no) 1994-11-28
TW309427B (no) 1997-07-01
NO941915D0 (no) 1994-05-24
FI942400A7 (fi) 1994-11-26
CN1100301A (zh) 1995-03-22
RU94017849A (ru) 1997-05-27
CA2124284C (en) 2002-10-01
US5837706A (en) 1998-11-17
CA2124284A1 (en) 1994-11-26
AU684270B2 (en) 1997-12-11
FI942400A0 (fi) 1994-05-24
RU2135162C1 (ru) 1999-08-27
NO993627D0 (no) 1999-07-26
US5661150A (en) 1997-08-26
FI942400L (fi) 1994-11-26
AU5837298A (en) 1998-05-21
PH31213A (en) 1998-05-05
AU6333194A (en) 1994-12-01

Similar Documents

Publication Publication Date Title
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
PT705100E (pt) Guanidinas substituidas terapeuticas
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
ES2160124T3 (es) Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
FI971290L (fi) Multippeliskleroosin (MS) ja muiden myeliinikadosta aiheutuvien sairauksien hoito
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
DE69302439D1 (de) Topisches Präparat zur Verhütung oder Behandlung der Akne Vulgaris
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
DE69405711D1 (de) Behandlung von rueckstandsoel
FI955786A7 (fi) Luonnontuotteiden ja vastaavien yhdisteiden käyttö sydän- ja verisuonisairauksien hoitoon
NO961226L (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
NO973081D0 (no) Fremgangmåte for behandling av kroniske progressive vaskulære sykdommer
NO993627D0 (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
DE69218200D1 (de) Behandlung von leberkrebs
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen